A patient’s concern about her skin may be her reason for reaching out to you. For the modern clinician, it is an opportunity to understand what is contributing to the change and what would help. The skin examination and the broader clinical assessment belong in the same visit. The new ACOG guidance addresses vasomotor, sleep, and mood symptoms; it does not provide an aesthetic-treatment protocol.
Functional and integrative clinicians have long considered nutrition, gut health, environmental exposures, and potential triggers in their assessments. As the catalog of beauty products grows, we need to keep that clinical perspective in the conversation. Choosing a product comes after deciding what needs attention.
The skincare industry is speaking more of our language. Mitochondrial function, collagen production, and cellular repair now appear in product descriptions. In Mintel’s 2026 U.S. skincare report, 79% believe preventing skin issues is more effective than correcting them later. That interest in prevention gives us an opening to discuss what skin care can achieve and where medical assessment belongs.
Perimenopause gives us a reason to look more closely
Changes in estrogen signaling can affect skin hydration, collagen, and elasticity. A concern about dryness or loss of firmness can open a conversation about the menopause transition, including symptoms that need attention alongside the skin findings.
The roundtable review cited by AmSpa discusses menopause-related skin changes and treatment options. It is expert guidance, supported by educational grants from AbbVie and Galderma, with no original trial data.
Older studies summarized in Thornton’s review estimate skin collagen losses of up to 30% in the first five years after menopause. That helps explain why this transition deserves attention. It cannot tell us how much collagen a particular patient has lost or which treatment to choose.
What the skin findings should change in our assessment
Menopause stage is useful when it changes our clinical thinking. The question is how the transition fits with the examination, symptoms, medications, and weight history, and which findings warrant further assessment. These are some of the connections worth making before settling on a skin plan.
Finding or concern | What to assess before choosing treatment |
|---|---|
Dryness, itching, or new sensitivity | Examine for a skin disorder; review cleansing, active products, recent procedures, and relevant medications. Consider the menopause transition alongside local irritation and barrier disruption. |
Loss of firmness or facial volume | Review sun exposure, weight change, GLP-1 treatment if applicable, and menopause history. Distinguish skin quality from changes in facial volume when setting treatment goals. |
Hair thinning or shedding | Assess the pattern and scalp findings, nutritional history, recent illness or weight loss, and medications. Use the differential to decide whether targeted testing or dermatology referral is needed. |
Skin changes with broader symptoms | Review menstrual changes, vasomotor symptoms, sleep, and other relevant complaints. Decide which concerns require medical assessment alongside the skin-directed plan. |
Nutrition, gastrointestinal symptoms, and environmental or occupational exposures belong in the history when relevant. Investigate when the findings support a plausible contributor and the result would change care. This is our practical assessment framework, informed by the American Academy of Dermatology’s guidance on menopausal skin and hair-loss assessment.
Build the topical plan around the finding
A broader view of topical care helps us put the newer ingredients in context. Start with the concern, the diagnosis where applicable, and what the patient can tolerate.
Clinical goal | Options to consider |
|---|---|
Reduce further UV damage | Broad-spectrum sunscreen with SPF 30 or higher, alongside other sun-protection measures. |
Improve dryness and support the barrier | Gentle cleansing and a fragrance-free moisturizer; formulations may include ceramides, glycerin, hyaluronic acid, or an occlusive such as petrolatum. |
Address photoaging and fine lines | A retinoid selected for the indication and individual suitability, with strength and frequency adjusted to tolerability. |
Address uneven tone or dark spots | Establish the cause first. Depending on the finding, options may include vitamin C, niacinamide, azelaic acid, or a retinoid. |
The AAD’s menopause advice, moisturizer guidance, and retinoid guidance provide useful starting points. A Delphi consensus study also maps common ingredients to cosmetic concerns; it reflects expert agreement, rather than comparative proof that one product is best.
Persistent redness, itching, or acne needs a diagnosis-specific plan. This is a selection framework, and few patients will need every ingredient.
Where the longevity ingredients may add something
For hydration and barrier support: beta-glucan is worth considering within the moisturizer discussion. A beta-glucan and aloe cream is one example. The ingredient literature provides a rationale, but class-level findings do not establish the performance of the finished cream.
For mitochondrial maintenance: topical urolithin A has emerging human evidence. In a manufacturer-associated study of 48 women, the 1% formulation reduced wrinkle depth versus vehicle after eight weeks. That is a specific skin outcome; a claim about longer healthspan would require different evidence.
For repair signaling: topical GHK-Cu has a biological rationale and some human data. The clinical literature remains limited, and delivery through the skin and the formulation matter. Look for evidence that matches the product and outcome you are discussing.
For exosome-based products: a 2026 review found 18 human studies, with varied sources and methods; ten included a delivery procedure. Preparations are not interchangeable, and the FDA reports no approved exosome products. A product-specific review is essential before considering clinical use.
For estrogen-responsive skin: topical estriol requires a hormone-treatment decision. Small studies of topical estrogen suggest potential benefits, but long-term safety remains insufficiently established. The FDA states that no estriol-containing drugs are approved in the U.S. A compounded formulation still needs an appropriate clinical rationale.
What to bring into the next visit
At the next visit where a patient raises a skin or hair concern, connect the finding to the rest of the assessment. Record what you think is contributing, what needs treatment or referral, and what you and the patient want to improve.
Agree on how and when to review the response. Standardized photographs can help assess visible changes when lighting, distance, and angles are consistent, with consent and secure clinical storage. Symptoms, tolerability, and the patient’s experience belong in that review too.
For now, the useful distinction in our own follow-up is between a visible improvement, relief of a symptom, and a change in an underlying condition. Each can matter to the patient. We should be clear about which one we have measured.
A useful way to explain the plan: “Here’s what I think is contributing, what we can address medically, and what this skin treatment is intended to improve. This is how we’ll assess the response.”
That is a practical way to bring longevity medicine into aesthetic care, whether skin treatment is already part of your practice or the patient is asking you where to begin.
Be a modern clinician with the help of Ultralight, the AI-native EHR built specifically for functional, integrative, and longevity medicine. We've recently launched wearables integrations and improved AI-native clinical workflows. Get in touch to see the latest updates.
Join Us at Eudēmonia Summit in West Palm Beach
We’ll be at Eudēmonia Summit, November 5 to 8 in West Palm Beach. Sunita Mohanty and Dr. Lexi Gonzales will join Helen Messier for “Stay Ahead of the Algorithm with an AI-Enhanced Practice.” If you want to join us, use code SMOHANTY for 10% off registration.
In the news
FDA and HHS sent an interim peptide compounding policy to the White House for review, and nothing has changed for prescribers yet. Holland & Knight reports that the “Interim Access Policy for Compounding Using Certain Peptides” went to the Office of Management and Budget on October 14. It had not been issued as of October 16, and no peptide has been added to the 503A bulks list. In July, an FDA advisory committee voted to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax), and those votes are advisory. For those of us who prescribe peptides, the useful step is to describe each one accurately, use a licensed 503A pharmacy whose sourcing you have vetted, and document why the peptide fits that patient.
A new Aging Cell analysis says a change on one epigenetic clock is weak evidence that an intervention changed biological age. The paper, published October 8 by Borrus, Higgins-Chen, and colleagues, added 11 more clocks to previously published intervention studies that had reported a change on a single clock. None of the added clocks moved significantly in the same direction. The authors propose that a result deserves more confidence when the more reliable principal-component clocks respond, mortality-trained or pace-of-aging clocks respond, and several clocks move the same way. A two-year Mediterranean diet trial and a three-week alcohol treatment program met all three. The authors also note that even a clear clock change does not show a change in lifespan or healthspan. If your panel includes an epigenetic clock, check whether the other clocks agree before showing a patient one clock’s change as proof the plan is working.
Hearing loss was linked to higher mortality in a four-country analysis, and hearing-aid use to lower mortality among people with hearing loss. A Lancet Healthy Longevity study pooled cohorts from Australia, Iceland, and the USA (13,851 adults) and replicated the findings in 50,277 adults in Norway. Compared with normal hearing, moderate hearing loss carried a hazard ratio of 1.55 for all-cause mortality (95% CI 1.42 to 1.70). Among people with hearing loss, current hearing-aid use was associated with a hazard ratio of 0.91 for all-cause mortality (0.83 to 0.99) and 0.85 for cardiovascular mortality (0.73 to 0.99), with similar results in Norway. The authors caution that residual confounding or collider bias could explain the hearing-aid result, since people who get hearing aids may differ in health and health-seeking behavior. A basic hearing screen at intake, with an audiology referral for a failed result, is a low-cost addition.
Upcoming Conferences & Events
Nov 5-8, Eudēmonia Summit · West Palm Beach, FL · One of the most talked-about longevity gatherings in the U.S. With experientials, hands-on demos, and the best place to try the emerging frameworks your patients will ask you about next year. Save 10% with code SMOHANTY. OvationLab and Ultralight will be there!
Nov 5-7, Private Physicians Alliance Annual Meeting · St. Petersburg, FL · Invitation-only annual meeting for independent, cash-pay, and concierge physicians navigating practice independence. Ultralight will be there!
Nov 8-11, American College of Lifestyle Medicine Conference · Orlando, FL · Lifestyle medicine's main annual event, with evidence-based approaches to behavior change, chronic disease, and healthspan. Growing overlap with the longevity medicine community.
Nov 10-13, Valley Forum 2026 · Napa Valley, CA · Invitation-only forum where healthcare leaders work through the industry's hard problems, AI's role in care among them. Ultralight will be there!
Dec 11-13, A4M Longevity Fest · Las Vegas, NV · The biggest longevity event in the U.S. The room spans clinicians, industry, founders, and the people building next year's platforms, and the connections from this one tend to compound through the rest of your year. Save $100 on registration with code Longevity26. OvationLab and Ultralight will be there!
Know of an event we should add? Reply and tell us.
Until next week
A patient who says her skin is changing is giving us a reason to look at the whole picture, from menopause stage and weight history to medications and sun exposure, before we choose a product. The plan we agree on should say what we think is contributing and how we will know it helped.
Reply and tell us what you check first when a patient raises a skin or hair concern. Know a colleague who is adding skin treatments to a longevity practice? Forward this to them.
Until next week, keep building the practice you imagined when you started.
Sunita & Dr. G